StockData
Biohaven Ltd. logo

Biohaven Ltd. (BHVN) stock

BHVNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 1/30
$12.39−1.26 (-9.23%)

Close on Nov 20, 2026Market cap $1.87BP/E –Yield –

Biohaven net income

Net income is the profit left for shareholders after every expense, interest and tax.

Biohaven's net income for the twelve months ending Sep 30, 2026 was -$542.68M. For fiscal 2025 it was -$738.82M. The highest annual figure on record is -$118.67M in fiscal 2020.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$738.82M–
FY2024Dec 31, 2024-$846.42M–
FY2023Dec 31, 2023-$408.17M–
FY2022Dec 31, 2022-$570.28M–
FY2021Dec 31, 2021-$213.80M–
FY2020Dec 31, 2020-$118.67M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$129.28M–
Q2 FY2026Jun 30, 2026-$137.31M–
Q1 FY2026Mar 31, 2026-$130.53M–
Q4 FY2025Dec 31, 2025-$145.56M–
Q3 FY2025Sep 30, 2025-$173.44M–
Q2 FY2025Jun 30, 2025-$198.15M–
Q1 FY2025Mar 31, 2025-$221.68M–
Q4 FY2024Dec 31, 2024-$186.84M–
Q3 FY2024Sep 30, 2024-$160.30M–
Q2 FY2024Jun 30, 2024-$319.77M–
Q1 FY2024Mar 31, 2024-$179.50M–
Q4 FY2023Dec 31, 2023-$144.76M–
Q3 FY2023Sep 30, 2023-$102.57M–
Q2 FY2023Jun 30, 2023-$90.35M–
Q1 FY2023Mar 31, 2023-$70.49M–
Q4 FY2022Dec 31, 2022-$201.11M–
Q3 FY2022Sep 30, 2022-$68.85M–
Q2 FY2022Jun 30, 2022-$203.29M–
Q1 FY2022Mar 31, 2022-$97.03M–
Q4 FY2021Dec 31, 2021-$51.89M–
Q3 FY2021Sep 30, 2021-$54.37M–
Q2 FY2021Jun 30, 2021-$45.42M–
Q1 FY2021Mar 31, 2021-$62.12M–

More Biohaven figures

See a number that looks wrong?